Linifanib

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameLinifanib
Drug Alias Name利尼法尼利尼伐尼AL-39324RG-3635A-741439 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVascular endothelial growth factor receptor 3 antagonistsVascular endothelial growth factor receptor 1 antagonistsVascular endothelial growth factor receptor 2 antagonists +[5] 
TargetsVascular endothelial growth factor receptor 1Vascular endothelial growth factor receptor 3Colony stimulating factor 1 receptor +[5] 
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursMacular Degeneration +[17] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[32] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesAbbvie Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAbbott LaboratoriesAlconAbbott Ireland Pharmaceutical Operations +[7] 
Active IndicationsN/A
Inactive IndicationsMetastatic breast cancerSolid tumoursMacular Degeneration +[17] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG